The forms, functions and techniques of Xhosa humour

Bibliography: pages 259-274.In this thesis I examine the way in which Xhosa speakers create humour, what forms (e.g. satire, irony, punning, parody) they favour in both oral and textual literature, and the genres in which these forms are delivered and executed. The functions of Xhosa humour, both during and after apartheid, are examined, as is its role in challenging, contesting and reaffirming traditional notions of society and culture. The particular techniques Xhosa comedians and comic writers use in order to elicit humour are explored with specific reference to the way in which the phonological complexity of this language is exploited for humorous effect. Oral literature sources include collections of praise poems, folktales and proverbs, while anecdotal humour is drawn from recent interviews conducted with domestic workers. My analysis of humour in literary texts initially focuses on the classic works of G.B. Sinxo and S.M. Burns-Ncamashe, and then goes on to refer to contemporary works such as those of P.T. Mtuze. The study on the techniques of Xhosa humour uses as its theoretical base Walter Nash's The language of humour (1985), while that on the functions of Xhosa humour owes much to the work of sociologists such as Michael Mulkay and Chris Powell and George E.C. Paton. The study reveals the fact that Xhosa oral humour is personal and playful - at times obscene - but can also be critical. In texts it explores the comedy of characters as well as the irony of socio-political realities. In both oral and textual discourses the phonology, morphology, syntax and semantics of Xhosa are exploited to create a humour which is richly patterned and finely crafted. In South Africa humour often served to liberate people from the oppressive atmosphere of apartheid. At the same time humour has always had a stabilizing role in Xhosa cultural life, providing a means of controlling deviants and misfits

Can The Marsh Migrate? Factors Influencing The Growth Of Spartina Patens In Upland Soil

Although high elevation salt marsh plants, such as Spartina patens (salt hay) can cope with accelerated sea level rise by migrating inland, it is not well known whether environmental factors, such as soil, plant litter, and salinity, will influence the ability of S. patens to colonize upland forest areas. For one growing season, I tested how S. patens vegetative growth (the final number of stems, aboveground stem biomass, and belowground rhizome biomass) and reproduction (presence of flowers) responded to upland or marsh soil, the presence or absence of plant litter, and 4.5ppt or 14.5ppt salinity levels. In order to determine if the source location of the plant influenced their response to treatment effects, I collected S. patens plants from three Maine salt marshes in the townships of Scarborough, Biddeford, and Wells. Litter and salinity treatments did not significantly affect vegetative growth, and they only affected flowering in a three-way interaction with site. All vegetative and reproductive measures were significantly affected by soil and the site x soil interaction - S. patens collected from Biddeford and Wells grew significantly less in the upland soil compared to the marsh soil, but Scarborough plants grew equally well in both soil treatments. One possible explanation for why plants from the three sites responded differently to soil treatments was that the Scarborough site had a significantly lower percent soil organic matter content, and therefore, was more similar to upland in soil organic matter content than the other two sites. These results suggest that S. patens populations from a site with low soil organic content will be more successful adjusting to upland soil than plants from high soil organic matter sites, which would give those populations accustomed to low organic matter an advantage when migrating inland. The ability to identify S. patens sites that will successfully migrate inland, by measuring soil organic content or other site characteristics, is vital if conservation efforts are going to protect the S. patens populations most likely to persist in the face of sea level rise

Isihlonipho sabafazi : the Xhosa women's language of respect : a sociolinguistic exploration

Bibliography: leaves 166-172.Isihlonipho Sabafazi (the Xhosa women's language of respect) is a language in which syllables occurring in the names of menfolk are avoided by women. Thie thesis attempts to place the practice in it social context by applying both descriptive and analytical methodologies. The thesis include a literature survey and a critique on the dynamics of gender and language. The results of interviews conducted in three areas, one urban and two rural, are analysed and tabulated. A glossary of substitute words is included

Multilingual construction of Communicative Development Inventories in Southern Africa

The Communicative Development Inventories (CDIs) are a set of validated, parent-completed questionnaires assessing children's vocabulary, gesture, and grammatical development. They have many benefits but in particular administration does not require a qualified psychologist or speech-language therapist, making them ideal for settings with poor access to professionals. In addition they are cheap to administer at scale, again benefitting low resource settings. Further, they are relatively easy to develop for languages that are not well described in terms of development, meaning they can be adapted easily to under-studied languages. The CDIs have previously been adapted for Asian (1), Indo-European (2), other European (3), Pacific Island (4) and some African languages (5,6). They have been used successfully in studies of health risks (nutrition, infection) in sub-Saharan Africa (7), again meaning they are useful for impoverished settings and child development issues prevalent in such settings. We are in process of developing CDIs for six languages spoken in Southern Africa (IsiXhosa, Setswana, Sesotho, Xitsonga, Afrikaans and South African English). We have developed a common method for each language starting with a long list of words taken from other CDIs, following on to parent/practitioner assessment of face validity of these words in their translations, and continuing to piloting, instrument reduction, and validation. Within validation we look at correlation with age, and relationship to other variables including family socio-economic status, and child language performance measured in the home or lab. We also apply these methods to the assessment of gesture using the CDI. Some of the languages to be studied are related to each other (of the Bantu group of African languages) and to two languages for which CDIs have been developed in East Africa (5); for these we will highlight common grammatical development to be examined that exists in all of the related languages. In the East African setting parents were found to be valid observers of their child's morpheme omissions so this is a particular focus for assessment of grammatical development. To date we have developed four pilot versions (IsiXhosa, Setswana, Sesotho, and Afrikaans). Vocabulary in isiXhosa is found to be significantly related to toddler age, mother education, and first-born status, among other known correlates of child language (8). In Sesotho, toddler vocabulary is also significantly related to age (9). In the other languages (Xitsonga and SA English) we have created pre-pilot word lists and carried out focus groups with parents enabling us to determine the acceptability of the words on our long-lists. We conclude that construction of CDIs in multiple (some unrelated) languages simultaneously is possible with rigorous application of the same methods to each language. Where languages are under-studied, we can benefit from previous research and descriptions of development in related languages. 1.Tardif, J. Child Lang. 36, (2009). 2.Caselli, J. Child Lang. 26, (1999); Bleses, J. Child Lang. 35, (2008). 3.Barrena, in A portrait of the young in the new multilingual Spain. (2008), vol. 9. 4.Reese, First Language 35, (2015). 5.Alcock, J. Child Lang. 42, (2015). 6.Prado, Journal of Health, Population and Nutrition 37, (2018). 7.Prado, J. Child Psychol.Psychi. 58, (2017); Alcock, BMC research notes 9, (2016). 8.Whitelaw, University of Cape Town (2018). 9.Horn, Cape Town (2018)

A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial

Abstract Objectives It is currently thought that most—but not all—individuals infected with SARS-CoV-2 develop symptoms, but that the infectious period starts on average two days before the first overt symptoms appear. It is estimated that pre- and asymptomatic individuals are responsible for more than half of all transmissions. By detecting infected individuals before they have overt symptoms, wearable devices could potentially and significantly reduce the proportion of transmissions by pre-symptomatic individuals. Using laboratory-confirmed SARS-CoV-2 infections (detected via serology tests [to determine if there are antibodies against the SARS-CoV-2 in the blood] or SARS-CoV-2 infection tests such as polymerase chain reaction [PCR] or antigen tests) as the gold standard, we will determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the following two algorithms to detect first time SARS-CoV-2 infection including early or asymptomatic infection: the algorithm using Ava bracelet data when coupled with self-reported Daily Symptom Diary data (Wearable + Symptom Data Algo; experimental condition) the algorithm using self-reported Daily Symptom Diary data alone (Symptom Only Algo; control condition) In addition, we will determine which of the two algorithms has superior performance characteristics for detecting SARS-CoV-2 infection including early or asymptomatic infection as confirmed by SARS-CoV-2 virus testing. Trial design The trial is a randomized, single-blinded, two-period, two-sequence crossover trial. All subjects will participate in an initial Learning Phase (varying from 2 weeks to 3 months depending on enrolment date), followed by two contiguous 3-month test phases, Period 1 and Period 2. Each subject will undergo the experimental condition (the Wearable + Symptom Data Algo) in one of these periods and the control condition (Symptom Only Algo) in the other period. The order will be randomly assigned, resulting in subjects being allocated 1:1 to either Sequence 1 (experimental condition first) or Sequence 2 (control condition first). Based on demographics, medical history and/or profession, each subject will be stratified at baseline into a high-risk and normal-risk group within each sequence. Participants The trial will be conducted in the Netherlands. A target of 20,000 subjects will be enrolled. Based on demographics, medical history and/or profession, each subject will be stratified at baseline into a high-risk and normal-risk group within each sequence. This results in approximately 6,500 normal-risk individuals and 3,500 high-risk individuals per sequence. Subjects will be recruited from previously studied cohorts as well as via public campaigns and social media. All data for this study will be collected remotely through the Ava COVID-RED app, the Ava bracelet, surveys in the COVID-RED web portal, and self-sampling serology and PCR kits. During recruitment, subjects will be invited to visit the COVID-RED web portal ( www.covid-red.eu ). After successfully completing the enrolment questionnaire, meeting eligibility criteria and indicating interest in joining the study, subjects will receive the subject information sheet and informed consent form. Subjects can enrol in COVID-RED if they comply with the following inclusion and exclusion criteria. Inclusion criteria: Resident of the Netherlands At least 18 years old Informed consent provided (electronic) Willing to adhere to the study procedures described in the protocol Must have a smartphone that runs at least Android 8.0 or iOS 13.0 operating systems and is active for the duration of the study (in the case of a change of mobile number, study team should be notified) Be able to read, understand and write Dutch Exclusion criteria: Previous positive SARS-CoV-2 test result (confirmed either through PCR/antigen or antibody tests; self-reported) Previously received a vaccine developed specifically for COVID-19 or in possession of an appointment for vaccination in the near future (self-reported) Current suspected (e.g., waiting for test result) COVID-19 infection or symptoms of a COVID-19 infection (self-reported) Participating in any other COVID-19 clinical drug, vaccine, or medical device trial (self-reported) Electronic implanted device (such as a pacemaker; self-reported) Pregnant at time of informed consent (self-reported) Suffering from cholinergic urticaria (per the Ava bracelet’s User Manual; self-reported) Staff involved in the management or conduct of this study Intervention and comparator All subjects will be instructed to complete the Daily Symptom Diary in the Ava COVID-RED app daily, wear their Ava bracelet each night and synchronise it with the app each day for the entire period of study participation. Provided with wearable sensor and/or self-reported symptom data within the last 24 hours, the Ava COVID-RED app’s underlying algorithms will provide subjects with a real-time indicator of their overall health and well-being. Subjects will see one of three messages, notifying them that: no seeming deviations in symptoms and/or physiological parameters have been detected; some changes in symptoms and/or physiological parameters have been detected and they should self-isolate; or alerting them that deviations in their symptoms and/or physiological parameters could be suggestive of a potential COVID-19 infection and to seek additional testing. We will assess intraperson performance of the algorithms in the experimental condition (Wearable + Symptom Data Algo) and control conditions (Symptom Only Algo). Main outcomes The trial will evaluate the use and performance of the Ava COVID-RED app and Ava bracelet, which uses sensors to measure breathing rate, pulse rate, skin temperature, and heart rate variability for the purpose of early and asymptomatic detection and monitoring of SARS-CoV-2 in general and high-risk populations. Using laboratory-confirmed SARS-CoV-2 infections (detected via serology tests, PCR tests and/or antigen tests) as the gold standard, we will determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for each of the following two algorithms to detect first-time SARS-CoV-2 infection including early or asymptomatic infection: the algorithm using Ava Bracelet data when coupled with the self-reported Daily Symptom Diary data, and the algorithm using self-reported Daily Symptom Diary data alone. In addition, we will determine which of the two algorithms has superior performance characteristics for detecting SARS-CoV-2 infection including early or asymptomatic infection as confirmed by SARS-CoV-2 virus testing. The protocol contains an additional seventeen secondary outcomes which address infection incidence rates, health resource utilization, symptoms reported by SARS-CoV-2 infected participants, and the rate of breakthrough and asymptomatic SARS-CoV-2 infections among individuals vaccinated against COVID-19. PCR or antigen testing will occur when the subject receives a notification from the algorithm to seek additional testing. Subjects will be advised to get tested via the national testing programme, and report the testing result in the Ava COVID-RED app and a survey. If they cannot obtain a test via the national testing programme, they will receive a nasal swab self-sampling kit at home, and the sample will be tested by PCR in a trial-affiliated laboratory. In addition, all subjects will be asked to take a capillary blood sample at home at baseline (Month 0), and at the end of the Learning Phase (Month 3), Period 1 (Month 6) and Period 2 (Month 9). These samples will be used for SARS-CoV-2-specific antibody testing in a trial-affiliated laboratory, differentiating between antibodies resulting from a natural infection and antibodies resulting from COVID-19 vaccination (as vaccination will gradually be rolled out during the trial period). Baseline samples will only be analysed if the sample collected at the end of the Learning Phase is positive, and samples collected at the end of Period 1 will only be analysed if the sample collected at the end of Period 2 is positive. When subjects obtain a positive PCR/antigen or serology test result during the study, they will continue to be in the study but will be moved into a so-called “COVID-positive” mode in the Ava COVID-RED app. This means that they will no longer receive recommendations from the algorithms but can still contribute and track symptom and bracelet data. The primary analysis of the main objective will be executed using data collected in Period 2 (Month 6 through 9). Within this period, serology tests (before and after Period 2) and PCR/antigen tests (taken based on recommendations by the algorithms) will be used to determine if a subject was infected with SARS-CoV-2 or not. Within this same time period, it will be determined if the algorithms gave any recommendations for testing. The agreement between these quantities will be used to evaluate the performance of the algorithms and how these compare between the study conditions. Randomisation All eligible subjects will be randomized using a stratified block randomization approach with an allocation ratio of 1:1 to one of two sequences (experimental condition followed by control condition or control condition followed by experimental condition). Based on demographics, medical history and/or profession, each subject will be stratified at baseline into a high-risk and normal-risk group within each sequence, resulting in equal numbers of high-risk and normal-risk individuals between the sequences. Blinding (masking) In this study, subjects will be blinded as to study condition and randomization sequence. Relevant study staff and the device manufacturer will be aware of the assigned sequence. The subject will wear the Ava bracelet and complete the Daily Symptom Diary in the Ava COVID-RED app for the full duration of the study, and they will not know if the feedback they receive about their potential infection status will only be based on data they entered in the Daily Symptom Diary within the Ava COVID-RED app or based on both the data from the Daily Symptom Diary and the Ava bracelet. Numbers to be randomised (sample size) 20,000 subjects will be recruited and randomized 1:1 to either Sequence 1 (experimental condition followed by control condition) or Sequence 2 (control condition followed by experimental condition), taking into account their risk level. This results in approximately 6,500 normal-risk and 3,500 high-risk individuals per sequence. Trial Status Protocol version: 1.2, dated January 22nd, 2021 Start of recruitment: February 22nd, 2021 End of recruitment (estimated): April 2021 End of follow-up (estimated): December 2021 Trial registration The trial has been registered at the Netherlands Trial Register on the 18th of February, 2021 with number NL9320 ( https://www.trialregister.nl/trial/9320 ) Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol

Heterozygous Variants in KMT2E Cause a Spectrum of Neurodevelopmental Disorders and Epilepsy.

We delineate a KMT2E-related neurodevelopmental disorder on the basis of 38 individuals in 36 families. This study includes 31 distinct heterozygous variants in KMT2E (28 ascertained from Matchmaker Exchange and three previously reported), and four individuals with chromosome 7q22.2-22.23 microdeletions encompassing KMT2E (one previously reported). Almost all variants occurred de novo, and most were truncating. Most affected individuals with protein-truncating variants presented with mild intellectual disability. One-quarter of individuals met criteria for autism. Additional common features include macrocephaly, hypotonia, functional gastrointestinal abnormalities, and a subtle facial gestalt. Epilepsy was present in about one-fifth of individuals with truncating variants and was responsive to treatment with anti-epileptic medications in almost all. More than 70% of the individuals were male, and expressivity was variable by sex; epilepsy was more common in females and autism more common in males. The four individuals with microdeletions encompassing KMT2E generally presented similarly to those with truncating variants, but the degree of developmental delay was greater. The group of four individuals with missense variants in KMT2E presented with the most severe developmental delays. Epilepsy was present in all individuals with missense variants, often manifesting as treatment-resistant infantile epileptic encephalopathy. Microcephaly was also common in this group. Haploinsufficiency versus gain-of-function or dominant-negative effects specific to these missense variants in KMT2E might explain this divergence in phenotype, but requires independent validation. Disruptive variants in KMT2E are an under-recognized cause of neurodevelopmental abnormalities

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

Introduction: The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures. Methods: In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025. Findings: Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2–6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MRI were more frequent in patients than in controls (157 [61%] of 259 vs 14 [27%] of 52; p<0·0001) and independently associated with COVID-19 status (odds ratio [OR] 2·9 [95% CI 1·5–5·8]; padjusted=0·0023) after adjusting for relevant confounders. Compared with controls, patients were more likely to have MRI evidence of lung abnormalities (p=0·0001; parenchymal abnormalities), brain abnormalities (p<0·0001; more white matter hyperintensities and regional brain volume reduction), and kidney abnormalities (p=0·014; lower medullary T1 and loss of corticomedullary differentiation), whereas cardiac and liver MRI abnormalities were similar between patients and controls. Patients with multiorgan abnormalities were older (difference in mean age 7 years [95% CI 4–10]; mean age of 59·8 years [SD 11·7] with multiorgan abnormalities vs mean age of 52·8 years [11·9] without multiorgan abnormalities; p<0·0001), more likely to have three or more comorbidities (OR 2·47 [1·32–4·82]; padjusted=0·0059), and more likely to have a more severe acute infection (acute CRP >5mg/L, OR 3·55 [1·23–11·88]; padjusted=0·025) than those without multiorgan abnormalities. Presence of lung MRI abnormalities was associated with a two-fold higher risk of chest tightness, and multiorgan MRI abnormalities were associated with severe and very severe persistent physical and mental health impairment (PHOSP-COVID symptom clusters) after hospitalisation. Interpretation: After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings emphasise the need for proactive multidisciplinary care pathways, with the potential for imaging to guide surveillance frequency and therapeutic stratification

Xhosa in 45 minutes

For anyone interested in taking their first steps towards learning the Xhosa language. This was a free lunch-time event at UCT Summer School, offering participants a chance to learn the basics of the Xhosa phonology and grammar. At the end of the lecture you will be able to: * click with ease * talk about present, future and past events in Xhosa * ask questions * reply to questions. The method is simple. You will be given the grammatical building blocks and told where they go; in Xhosa it is extremely regular and predictable. You can learn vocabulary on your own but in this lecture you will learn some English and Afrikaans words that have been absorbed into Xhosa. Here are just a few to whet your appetite: redi (ready), rayithi (right), rongo (wrong), snaaks (funny), swit (sweet), jimisha (do gym), stak-ile (stuck) and depresed-ek-ile (depressed). As we progress from one concept to another you will be given small translation exercises to do in class. You will be hugely impressed with your ability to construct meaningful, fairly complex sentences in Xhosa in such a short time. The link to this resource includes a podcast, PowerPoint slides and a link to a video of the lecture on YouTube

'Akuchanywa apha please' No peeing here please: The language of signage in Cape Town

This article examines the language used on both formal and informal signage in Cape Town. Using the theory of geosemiotics with examples of actual signage, I discuss the semantic vulnerability of language when a sign is used outside its intended context; the sociolinguistic implications of poor translations; the phenomenon of monolingual and bilingual signage as opposed to trilingual signage; the symbolic hegemony of English and Afrikaans over Xhosa; and the lessons that can be learnt from language used on informal township signs and advertisements

Seeing the world as an African language speaker

This lecture will be of interest to anyone who wishes to know more about the relationship between language and culture. Go to Seeing the world as an African language speaker Is the way we see the world influenced by our language, or is it the other way around: is our language influenced by the way we see the world? You’ve all heard (the rather faulty) example of the Inuit having many words for snow – and maybe even have heard of the South American language called Yagan with a word Mamihlapinatapei which refers to the desirous look two people give each other when they want to start something but are too hesitant to do so (what a wistful, romantic culture, you might think!) But what about here in South Africa? What is it about African languages that makes them uniquely different and astonishingly original in the way they are put together? This lecture will introduce you to some of the key features (both structural and metaphorical) of our languages, features essential to understanding their cultures